Aspira Women's Health Reports Third Quarter 2023 Financial Results
Product revenue increased 9% to $2.2 million for the quarter, and 19% to $7.0 million year to dateOvaSuite sales volume increased 5% to 5,783 unit...
Stay updated with breaking news from Monique Kosse. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Product revenue increased 9% to $2.2 million for the quarter, and 19% to $7.0 million year to dateOvaSuite sales volume increased 5% to 5,783 unit...
The proposed rule would allow for OvaWatchSM to be reimbursed at the same rate as Ova1® at $897 per test and will become final following a brief public comment period AUSTIN, Texas, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases, today announced that during the 2024 Clinical Laboratory Fee Schedule (CLFS) ra
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q3 2023 Earnings Call Transcript November 2, 2023 Operator: Good morning, and welcome to Cellectar Biosciences Third Quarter 2023 Update Call. Today’s conference is being recorded. At this time, I would like to turn the conference over to Monique Kosse of LifeSci Advisors. Please go ahead. Monique Kosse: Thank you, operator, […]
Operator: Good morning, and welcome to Cellectar Biosciences Third Quarter 2023 Update Call. Today's conference is being recorded.
AUSTIN, Texas, Oct. 25, 2023 -- Aspira Women’s Health Inc. , a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic...